logo

For the Inventor, By the Inventor

Jena, Germany

Andrea Schweinitz

USPTO Granted Patents = 15 

 

Average Co-Inventor Count = 4.7

ph-index = 4

Forward Citations = 73(Granted Patents)


Company Filing History:

goldMedal13 out of 16 
 
The Medicines Company (leipzig) Gmbh
 patents
silverMedal2 out of 2 
 
Curacyte Ag
 patents

Years Active: 2004-2017

Loading Chart...
Loading Chart...
15 patents (USPTO):Explore Patents
1. 9611290 - Trypsin-like serine protease inhibitors, and their preparation and use (2017-04-04),
2. 9365613 - Acylated 4-amidino- and -4-guanidinobenzylamines for inhibition of plasma kallikrein (2016-06-14),
3. 9090658 - Base-substituted benzylamine analogs for use as coagulation factor Xa inhibitors, the production and use thereof (2015-07-28),
4. 8598206 - Trypsin-like serine protease inhibitors, and their preparation and use (2013-12-03),
5. 8569313 - Meta-substituted phenyl sulfonyl amides of secondary amino acid amides, the production thereof, and use thereof as matriptase inhibitors (2013-10-29),
6. 8513461 - Trypsin-like serine protease inhibitors, and their preparation and use (2013-08-20),
7. 8497245 - Trypsin-like serine protease inhibitors, their preparation and use as selective inhibitors of the clotting factors IIa and Xa (2013-07-30),
8. 8476306 - Urokinase inhibitors, production and use thereof (2013-07-02),
9. 8410310 - Trypsin-like serine protease inhibitors, and their preparation and use (2013-04-02),
10. 8207378 - Trypsin-like serine protease inhibitors, and their preparation and use (2012-06-26),
11. 8124587 - 2-(aminomethyl)-5-chlorobenzylamide derivatives and their use as inhibitors of the clotting factor Xa (2012-02-28),
12. 7838560 - Urokinase inhibitors, production and use thereof (2010-11-23),
13. 7772251 - N-sulphonylated amino acid derivatives, method for the production and use thereof (2010-08-10),
14. 6841701 - Inhibitors for the blood-clotting factor Xa (2005-01-11),
15. 6831196 - Urokinase inhibitors (2004-12-14),

Title: The Innovative Contributions of Andrea Schweinitz

Introduction

Andrea Schweinitz is a prominent inventor based in Jena, Germany, known for his significant contributions to the field of biochemistry and pharmacology. With a remarkable portfolio comprising 15 patents, Schweinitz's innovations have focused on developing compounds that play essential roles in therapeutic applications, particularly in anticoagulation and blood management.

Latest Patents

One of Schweinitz's latest patents involves Trypsin-like serine protease inhibitors, providing compounds that effectively inhibit human plasmin and plasma kallikrein. These compounds offer promising solutions for the prevention of blood loss and serve as crucial components of fibrin adhesives. Furthermore, he has patented acylated 4-amidino- and 4-guanidinobenzylamines aimed at inhibiting plasma kallikrein, factor XIa, and factor XIIa. This invention is particularly valuable for preventing the activation of coagulation at synthetic surfaces and represents a significant advancement in anticoagulant and antithrombotic treatments.

Career Highlights

Throughout his career, Andrea Schweinitz has made impactful strides while working with notable organizations such as The Medicines Company GmbH in Leipzig and Curacyte AG. His work in these companies has contributed to advancements in drug development and therapeutic innovations that aim to improve patient care and outcomes.

Collaborations

Schweinitz has collaborated with esteemed colleagues, including Torsten Steinmetzer and Claudia Reichelt. These partnerships illustrate a commitment to teamwork and knowledge exchange within the scientific community, further enhancing the innovation process in their respective fields.

Conclusion

Andrea Schweinitz stands out as an inventive force with a rich history of patents that showcases his dedication to advancing biochemistry and therapeutic solutions. His recent innovations highlight the potential for significant advancements in medical treatments, particularly in relation to coagulation management and blood loss prevention. As research continues, Schweinitz's contributions will undoubtedly play a critical role in shaping future medical practices and enhancing patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…